Halozyme Therapeutics (HALO) FCF Margin Growth (1y) (2011 - 2026)

Halozyme Therapeutics (HALO) FCF Margin Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -89.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -1,183.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 869.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -7.76 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 811.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 769.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 19,111.00
10 Halozyme Therapeutics 11.25 Bn 11.02 Bn 401.83 Mn 1,908.00

Historic Data

Download Data
DateValue
Jun 30, 2026 1,908.00
Mar 31, 2026 -1,106.00
Dec 31, 2025 -1,419.00
Sep 30, 2025 1,225.00
Jun 30, 2025 470.00
Mar 31, 2025 -640.00
Dec 31, 2024 2,428.00
Sep 30, 2024 -2,404.00
Jun 30, 2024 -469.00
Mar 31, 2024 1,087.00
Dec 31, 2023 -606.00
Sep 30, 2023 2,851.00
Jun 30, 2023 447.00
Mar 31, 2023 1,290.00
Dec 31, 2022 -3,796.00
Sep 30, 2022 -7,183.00
Jun 30, 2022 -100.00
Mar 31, 2022 -2,469.00
Dec 31, 2021 3,969.00
Sep 30, 2021 9,635.00